NCT02760030 - Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer

Interventions

DRUG

Fulvestrant

Given IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Palbociclib

Given PO

OTHER

Questionnaire Administration

Correlative studies

DRUG

Aromatase Inhibitors

Given PO

Trial Locations (3)

41017

St. Elizabeth Healthcare, Edgewood

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western University, Cleveland

All Listed Sponsors

lead

Ohio State University Comprehensive Cancer Center

OTHER